

Consensus Controversy?

INVESTIGATOR PERSPECTIVES ON PRACTICAL ISSUES AND RESEARCH QUESTIONS IN MULTIPLE MYELOMA

CME INFORMATION

TARGET AUDIENCE

This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

OVERVIEW OF ACTIVITY

It is estimated that approximately 22,350 new cases of MM were identified in the United States in the year 2013, and 10,710 individuals died from the disease. Clinical controversies and uncertainties persist in the management of all common cancers, and thousands of ongoing research trials worldwide attempt to provide new answers to longstanding clinical questions. As these trials reach their maturity, clinical investigators seek opportunities to present this information publicly so that relevant findings can be quickly incorporated into future research and current patient care. Although the extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies.

These proceedings from a CME symposium during the 55th ASH Annual Meeting use the perspectives of renowned experts in the field of hematologic oncology to frame a relevant discussion of the optimal management of MM. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies for MM.

LEARNING OBJECTIVES

- Appraise recent data on therapeutic advances and changing practice standards in MM, and integrate this information, when appropriate, into current clinical care.
- Compare and contrast the benefits and risks of immunomodulatory agents, proteasome inhibitors or both as systemic treatment for active MM.
- Identify patients with MM who may benefit from maintenance systemic treatment in both the post-transplant and nontransplant settings.

- Develop a risk-adapted treatment plan for patients with smoldering myeloma, considering the roles of observation and active treatment.
- Recall new data with investigational agents demonstrating promising activity in MM.
- Assess the ongoing clinical trials evaluating innovative investigational approaches for MM, and obtain consent from appropriate patients for study participation.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 2.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASHMM14/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Amrita Krishnan, MD

Director, Multiple Myeloma Program
City of Hope Cancer Center
Duarte, California

Advisory Committee: Celgene Corporation, Onyx Pharmaceuticals Inc; **Ownership Interest:** Celgene Corporation; **Speakers Bureau:** Celgene Corporation, Genentech BioOncology, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.

A Keith Stewart, MBChB

Dean for Research, Mayo Clinic in Arizona
Consultant, Division of Hematology/Oncology
Vasek and Anna Maria Polak Professorship in Cancer Research
Scottsdale, Arizona

Advisory Committee: Amgen Inc, Celgene Corporation;
Consulting Agreements: Celgene Corporation, Millennium: The Takeda Oncology Company; **Contracted Research:** Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.

William I Bensinger, MD

Professor of Medicine, University of Washington
Member, Fred Hutchinson Cancer Research Center
Director, Autologous Stem Cell Transplant Program
Seattle, Washington

Advisory Committee: Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc, Sanofi;
Consulting Agreement: Celgene Corporation; **Contracted Research:** Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; **Speakers Bureau:** Celgene Corporation.

Meletios A Dimopoulos, MD

Chairman, Department of Medical Therapeutics
University of Athens School of Medicine
Athens, Greece

Advisory Committee: Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Advisory Committee: Amgen Inc, Celgene Corporation;
Consulting Agreements: Lilly, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; **Contracted Research:** Acetylon Pharmaceuticals Inc, Amgen Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL

REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec, Lilly, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc and Teva Oncology.

Hardware/Software Requirements:

A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: March 2014

Expiration date: March 2015

Amrita Krishnan, MD

Arnulf B et al. **Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.** *Haematologica* 2012;97(12):1925-8.

Brinchen S et al. **Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.** *Blood* 2010;116(23):4745-53.

Cavo M et al. **Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study.** *Lancet* 2010;376(9758):2075-85.

Harousseau JL et al. **Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial.** *J Clin Oncol* 2010;28(30):4621-9.

Kapoor P et al. **Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.** *J Clin Oncol* 2013;31(36):4529-35.

Lenalidomide/bortezomib/dexamethasone for multiple myeloma (MM) (RVD Lite). NCT01782963

Mateos MV et al. **Comparison of bortezomib (VC) cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone (VMP) regimens in previously untreated multiple myeloma (MM) patients (pts) ineligible for high-dose therapy (HDT).** *Haematologica* 2011;96(s1):81. [Abstract P-175](#).

Mateos MV et al. **Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial.** *Lancet Oncol* 2010;11(10):934-41.

Mateos MV et al. **Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the Phase III VISTA trial.** *J Clin Oncol* 2010;28(13):2259-66.

Moreau P et al. **Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study.** *Lancet Oncol* 2011;12(5):431-40.

Palumbo A et al. **Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: A randomized controlled trial.** *J Clin Oncol* 2010;28(34):5101-9.

Rajkumar S et al. **Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial.** *Lancet Oncol* 2013;11(1):29-37.

Reeder CB et al. **Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.** *Blood* 2010;115(16):3416-7.

Richardson PG et al. **Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.** *Blood* 2010;116(5):679-86.

A Keith Stewart, MBChB

Attal M et al. **Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.** *N Engl J Med* 2012;366(19):1782-91.

Boccadoro M et al. **Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.** *Proc ASCO* 2013;[Abstract 8509](#).

McCarthy PL et al. **Lenalidomide after stem-cell transplantation for multiple myeloma.** *N Engl J Med* 2012;366(19):1770-81.

Sonneveld P et al. **Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/GMMG-HD4 trial.** *J Clin Oncol* 2012;30(24):2946-55.

Sonneveld P et al. **HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) Vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM).** *Proc ASH* 2010;[Abstract 40](#).

Stewart AK et al. **A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: The National Cancer Institute of Canada Clinical Trials Group Myeloma 10 trial.** *Blood* 2013;21(9):1517-23.

William I Bensinger, MD

Brinthen S et al. **A phase II study with carfilzomib, cyclophosphamide and dexamethasone (CCd) for newly diagnosed multiple myeloma.** *Proc ASH* 2013;[Abstract 685](#).

Cavo M et al. **Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study.** *Lancet* 2010;376(9758):2075-85.

Chari A et al. **A 28 day schedule for lenalidomide, bortezomib, and dexamethasone in newly diagnosed multiple myeloma.** *Proc ASH* 2011;[Abstract 2949](#).

Ghobrial IM et al. **Clinical profile of single-agent modified-release oprozomib tablets in patients (pts) with hematologic malignancies: Updated results from a multicenter, open-label, dose escalation phase 1b/2 study.** *Proc ASH* 2013;[Abstract 3184](#).

Jakubowiak AJ et al. **A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.** *Blood* 2012;120(9):1801-9.

Kumar SK et al. **A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM).** *Proc ASH* 2012;[Abstract 332](#).

Lawasut P et al. **New proteasome inhibitors in myeloma.** *Curr Hematol Malig Rep* 2012;7(4):258-66.

Palumbo A et al. **Overall survival benefit for bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in newly diagnosed multiple myeloma patients.** *Proc ASH* 2012;[Abstract 200](#).

Reeder CB et al. **Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial.** *Leukemia* 2009;23(7):1337-41.

Richardson PG et al. **Twice-weekly oral MLN9708 (ixazomib citrate), an investigational proteasome inhibitor, in combination with lenalidomide (Len) and dexamethasone (Dex) in patients (Pts) with newly diagnosed multiple myeloma (MM): Final phase 1 results and phase 2 data.** *Proc ASH* 2013;[Abstract 535](#).

Richardson PG et al. **Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.** *Blood* 2010;116(5):679-86.

Richardson PG et al. **Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.** *N Engl J Med* 2005;352(24):2487-98.

Siegel D et al. **Integrated safety profile of single-agent carfilzomib: Experience from 526 patients enrolled in 4 phase II clinical studies.** *Haematologica* 2013;98(11):1753-61.

Sonneveld P et al. **Bortezomib induction and maintenance treatment improves survival in patients with newly diagnosed multiple myeloma: Extended follow-up of the HOVON-65/GMMG-HD4 trial.** *Proc ASH* 2013;[Abstract 404](#).

Sonneveld P et al. **Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/GMMG-HD4 trial.** *J Clin Oncol* 2012;30(24):2946-55.

Sonneveld P et al. **Carfilzomib combined with thalidomide and dexamethasone (CTD) is an highly effective induction and consolidation treatment in newly diagnosed patients with multiple myeloma (MM) who are transplant candidate.** *Proc ASH* 2012;[Abstract 333](#).

Touzeau C et al. **Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (Ph) I/II trial.** *Proc ASCO* 2013;[Abstract 8513](#).

Meletios A Dimopoulos, MD

De Weers M et al. **Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.** *J Immunol* 2011;186(3):1840-8.

Dimopoulos MA et al. **Pomalidomide in combination with low-dose dexamethasone: Demonstrates a significant progression free survival and overall survival advantage, in relapsed/refractory MM: A phase 3, multicenter, randomized, open-label study.** *Proc ASH* 2012;[Abstract LBA-6](#).

Fanale M et al. **Multi-trial safety evaluation of the fully antagonistic human anti-CD40 monoclonal antibody lucatumumab (HCD122) in patients with relapsed or refractory B-cell malignancies.** *Proc ASH* 2011;[Abstract 3702](#).

Jagannath S et al. **BT062, an antibody-drug conjugate directed against CD138, shows clinical activity in patients with relapsed or relapsed/refractory multiple myeloma.** *Proc ASH* 2011;[Abstract 305](#).

Jakubowiak AJ et al. **Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.** *Proc ASCO* 2010;[Abstract 8003](#).

Kumar SK et al. **Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter International Myeloma Working Group study.** *Leukemia* 2012;26(1):149-57.

Lokhorst HM et al. **Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma — Data from the dose-escalation part of the FIH study.** *Proc ASCO* 2013;[Abstract 8512](#).

Lonial S et al. **Phase I/II study of elotuzumab plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: Updated Phase II results and Phase I/II long term safety.** *Proc ASCO* 2013;[Abstract 8542](#).

Lonial S et al. **A phase 2 study of elotuzumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.** *Proc ASH* 2011;[Abstract 303](#).

Mahdevan D et al. **First-in-human phase I dose escalation study of a humanized anti-CD200 antibody (samalizumab) in patients with advanced stage B cell chronic lymphocytic leukemia (B-CLL) or multiple myeloma (MM).** *Proc ASH* 2010;[Abstract 2465](#).

Mark TM et al. **ClaPD (clarithromycin, pomalidomide, dexamethasone) therapy in relapsed or refractory multiple myeloma.** *Proc ASH* 2012;[Abstract 77](#).

Palumbo A et al. **Pomalidomide cyclophosphamide and prednisone (PCP) treatment for relapsed/refractory multiple myeloma.** *Proc ASH* 2012;[Abstract 446](#).

Plesner T et al. **Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma — Data from a dose-escalation phase I/II study.** *Proc ASH* 2012;[Abstract 73](#).

Quach H et al. **Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.** *Leukemia* 2010;24(1):22-32.

Raje N et al. **Phase 1 study of tabalumab, a human anti-BAFF antibody and bortezomib in patients with previously-treated multiple myeloma.** *Proc ASH* 2012;[Abstract 447](#).

Richardson PG et al. **MM-005: A phase 1, multicenter, open-label, dose-escalation study to determine the maximum tolerated dose for the combination of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma.** *Proc ASH* 2012;[Abstract 727](#).

Rossi JF et al. **Preliminary results of CNTO 328, an anti-interleukin-6 monoclonal antibody, in combination with bortezomib in the treatment of relapsed or refractory multiple myeloma.** *Proc ASH* 2008;[Abstract 867](#).

San Miguel J et al. **Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial.** *Lancet Oncol* 2013;14(11):1055-66.

Shah J et al. **A multi-center Phase I/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma.** *Proc ASH* 2012;[Abstract 74](#).

Noopur Raje, MD

A study of siltuximab (anti- IL 6 monoclonal antibody) in patients with high-risk smoldering multiple myeloma. [NCT01484275](#)

Biomarker study of elotuzumab in high risk smoldering myeloma. [NCT01441973](#)

Boyd K et al. **Does zoledronic acid reduce skeletal-related events and improve progression-free survival in patients with multiple myeloma with or without bone disease? MRC Myeloma IX study results.** *Proc ASCO* 2011;[Abstract 8010](#).

Carfilzomib, lenalidomide, and dexamethasone for smoldering multiple myeloma. [NCT01572480](#)

Dispenzieri A et al. **Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.** *Blood* 2008;111(2):785-9.

Kyle RA, Rajkumar SV. **Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.** *Leukemia* 2009;23(1):3-9.

Kyle RA et al. **Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.** *N Engl J Med* 2007;356(25):2582-90.

Larsen JT et al. **Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.** *Leukemia* 2013;27(4):941-6.

Lenalidomide or observation in treating patients with asymptomatic high-risk smoldering multiple myeloma. [NCT01169337](#)

Mateos MV et al. **Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.** *N Engl J Med* 2013;369(5):438-47.

MLN9708 and dexamethasone for high-risk smoldering multiple myeloma. [NCT01660997](#)

Perez-Persona E et al. **New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.** *Blood* 2007;110(7):2586-92.

Phase 1/2a study of cancer vaccine to treat smoldering multiple myeloma. [NCT01718899](#)

Raje N et al. **Phase 1 study of tabalumab, a human anti-BAFF antibody and bortezomib in patients with previously-treated multiple myeloma.** *Proc ASH* 2012;[Abstract 447](#).

Rosen LS et al. **Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial.** *Cancer J* 2001;7(5):377-87.